Literature DB >> 23798495

Ranolazine recruits muscle microvasculature and enhances insulin action in rats.

Zhuo Fu1, Lina Zhao, Weidong Chai, Zhenhua Dong, Wenhong Cao, Zhenqi Liu.   

Abstract

Ranolazine, an anti-anginal compound, has been shown to significantly improve glycaemic control in large-scale clinical trials, and short-term ranolazine treatment is associated with an improvement in myocardial blood flow. As microvascular perfusion plays critical roles in insulin delivery and action, we aimed to determine if ranolazine could improve muscle microvascular blood flow, thereby increasing muscle insulin delivery and glucose use. Overnight-fasted, anaesthetized Sprague-Dawley rats were used to determine the effects of ranolazine on microvascular recruitment using contrast-enhanced ultrasound, insulin action with euglycaemic hyperinsulinaemic clamp, and muscle insulin uptake using (125)I-insulin. Ranolazine's effects on endothelial nitric oxide synthase (eNOS) phosphorylation, cAMP generation and endothelial insulin uptake were determined in cultured endothelial cells. Ranolazine-induced myographical changes in tension were determined in isolated distal saphenous artery. Ranolazine at therapeutically effective dose significantly recruited muscle microvasculature by increasing muscle microvascular blood volume (∼2-fold, P < 0.05) and increased insulin-mediated whole body glucose disposal (∼30%, P = 0.02). These were associated with an increased insulin delivery into the muscle (P < 0.04). In cultured endothelial cells, ranolazine increased eNOS phosphorylation and cAMP production without affecting endothelial insulin uptake. In ex vivo studies, ranolazine exerted a potent vasodilatatory effect on phenylephrine pre-constricted arterial rings, which was partially abolished by endothelium denudement. In conclusion, ranolazine treatment vasodilatates pre-capillary arterioles and increases microvascular perfusion, which are partially mediated by endothelium, leading to expanded microvascular endothelial surface area available for nutrient and hormone exchanges and resulting in increased muscle delivery and action of insulin. Whether these actions contribute to improved glycaemic control in patients with insulin resistance warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798495      PMCID: PMC3810821          DOI: 10.1113/jphysiol.2013.257246

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  51 in total

Review 1.  The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake.

Authors:  Lucy H Clerk; Michelle A Vincent; Jonathan R Lindner; Michael G Clark; Stephen Rattigan; Eugene J Barrett
Journal:  Diabetes Metab Res Rev       Date:  2004 Jan-Feb       Impact factor: 4.876

Review 2.  Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.

Authors:  Bernard R Chaitman
Journal:  Curr Probl Cardiol       Date:  2002-12       Impact factor: 5.200

Review 3.  Blood flow and muscle metabolism: a focus on insulin action.

Authors:  Michael G Clark; Michelle G Wallis; Eugene J Barrett; Michelle A Vincent; Stephen M Richards; Lucy H Clerk; Stephen Rattigan
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-02       Impact factor: 4.310

Review 4.  Ranolazine: a novel metabolic modulator for the treatment of angina.

Authors:  J G McCormack; W C Stanley; A A Wolff
Journal:  Gen Pharmacol       Date:  1998-05

5.  Effect of ranolazine on rat intrarenal arteries in vitro.

Authors:  Chun-Yu Deng; Su-Juan Kuang; Fang Rao; Hui Yang; Xian-Hong Fang; Zhi-Xin Shan; Xiao-Hong Li; Zhi-Ling Zhou; Qiu-Xiong Lin; Min Yang; Shu-Lin Wu; Xi-Yong Yu; Shu-Guang Lin
Journal:  Eur J Pharmacol       Date:  2012-03-16       Impact factor: 4.432

6.  Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells.

Authors:  Guolian Li; Eugene J Barrett; Hong Wang; Weidong Chai; Zhenqi Liu
Journal:  Endocrinology       Date:  2005-08-11       Impact factor: 4.736

7.  Intracellular pathways of insulin transport across vascular endothelial cells.

Authors:  H L Hachiya; P A Halban; G L King
Journal:  Am J Physiol       Date:  1988-10

8.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Authors:  Bernard R Chaitman; Carl J Pepine; John O Parker; Jaroslav Skopal; Galina Chumakova; Jerzy Kuch; Whedy Wang; Sandra L Skettino; Andrew A Wolff
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

9.  Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin.

Authors:  M A Vincent; E J Barrett; J R Lindner; M G Clark; S Rattigan
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07       Impact factor: 4.310

10.  Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.

Authors:  Weidong Chai; Zhenhua Dong; Nasui Wang; Wenhui Wang; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

View more
  17 in total

1.  Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment.

Authors:  Richard L Verrier
Journal:  J Physiol       Date:  2013-10-15       Impact factor: 5.182

2.  Direct Activation of Angiotensin II Type 2 Receptors Enhances Muscle Microvascular Perfusion, Oxygenation, and Insulin Delivery in Male Rats.

Authors:  Fei Yan; Zhaoshun Yuan; Nasui Wang; Robert M Carey; Kevin W Aylor; Li Chen; Xinmin Zhou; Zhenqi Liu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

3.  Long-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction.

Authors:  Zhuo Fu; Jing Wu; Tanseli Nesil; Ming D Li; Kevin W Aylor; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-29       Impact factor: 4.310

4.  Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses.

Authors:  Lina Zhao; Zhuo Fu; Jing Wu; Kevin W Aylor; Eugene J Barrett; Wenhong Cao; Zhenqi Liu
Journal:  J Physiol       Date:  2015-07-26       Impact factor: 5.182

5.  Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor.

Authors:  Zhuo Fu; Lina Zhao; Kevin W Aylor; Robert M Carey; Eugene J Barrett; Zhenqi Liu
Journal:  Hypertension       Date:  2014-04-07       Impact factor: 10.190

Review 6.  Vascular function, insulin action, and exercise: an intricate interplay.

Authors:  Chao Zheng; Zhenqi Liu
Journal:  Trends Endocrinol Metab       Date:  2015-02-23       Impact factor: 12.015

7.  Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.

Authors:  Jia Liu; Kevin W Aylor; Weidong Chai; Eugene J Barrett; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-02-07       Impact factor: 4.310

Review 8.  Adiponectin and insulin cross talk: the microvascular connection.

Authors:  Lina Zhao; Zhuo Fu; Zhenqi Liu
Journal:  Trends Cardiovasc Med       Date:  2014-08-07       Impact factor: 6.677

9.  GLP-1 and Insulin Recruit Muscle Microvasculature and Dilate Conduit Artery Individually But Not Additively in Healthy Humans.

Authors:  Alvin W K Tan; Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; James T Patrie; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  J Endocr Soc       Date:  2018-01-22

10.  Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity.

Authors:  Lina Zhao; Zhuo Fu; Jing Wu; Kevin W Aylor; Eugene J Barrett; Wenhong Cao; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2015-08-11       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.